DOI: 10.1055/s-00000133

Gastroenterologie up2date

Referenz

Jorgensen KK, Olsen IC, Goll GL. et al.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Lancet 2017;
389: 2304-2316

Bibliographische Angaben herunterladen

Suchen in:
Aufrufen in:
Aufrufen in: